Article Text
Therapeutics/Prevention
Randomised controlled trial
Prolonged dual antiplatelet therapy after drug-eluting stent reduces the risk of stent thrombosis and major cardiovascular events but increases the rate of bleeding
Statistics from Altmetric.com
Commentary on: OpenUrlCrossRefPubMedWeb of Science
Context
The implantation of drug-eluting stents (DES) has become a standard treatment for the management of patients with coronary artery disease. The use of dual antiplatelet therapy (DAPT) is critically important for the prevention of coronary stent thrombosis. Current clinical guidelines recommend at least 6–12 months of treatment after DES implantation; however, a longer duration of DAPT may be beneficial.1
Methods
This study is an international, randomised, placebo-controlled trial that was designed to determine the benefits and risks of continuing DAPT beyond …
Footnotes
Competing interests None.
Provenance and peer review Commissioned; internally peer reviewed.